



# SAFETY DATA SHEET

Revision date 10-Jun-2026

Version 2.01

Page 1 / 13

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
**Product Code(s)** PF00262  
**Trade Name:** Not applicable  
**Chemical Family:** Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as antibiotic agent

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

GHS - Classification: This mixture is classified as not hazardous according to regulation (EC) 1272/2008 [CLP].

**Specific target organ toxicity (repeated exposure)** Category 2 - (H373)

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**  
Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**  
Not applicable

### 2.2. Label elements

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 2 / 13

Version 2.01



## Signal word

Warning

## Hazard statements

H373 - May cause damage to organs through prolonged or repeated exposure

## Precautionary Statements - EU (§28, 1272/2008)

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P314 - Get medical advice/attention if you feel unwell

P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

## 2.3. Other hazards

### Other hazards

An Occupational Exposure Value has been established for this substance ( see Section 8 ).

## Daptomycin

Pfizer OEL TWA-8 Hr:

300 µg/m<sup>3</sup>

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Unknown acute toxicity

5 - 10 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

## Unknown aquatic toxicity

Contains 5 - 10 % of components with unknown hazards to the aquatic environment.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

#### Substances

Not applicable

### 3.2 Mixtures

#### Hazardous

Chemical name	Weight-%	REACH registration number	EC No. (Index No.)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Daptomycin (CAS #: 103060-53-3)	5 - 10		Not Listed	STOT RE 2 (H373)	Not classified	No data available	No data available
Citric acid	< 1		201-069-1	Eye Irrit. 2A	Not classified	No data	No data

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
 Revision date 10-Jun-2026

Page 3 / 13

Version 2.01

(CAS #: 77-92-9)			(607-750-00-3)	(H319)SE 3 (H335)		available	available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr.1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

### Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Citric acid 77-92-9	5400	>2000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

### **Additional information**

\*\* to adjust pH

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians** None.

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 4 / 13

Version 2.01

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2 or water spray.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Fine particles (such as dust and mists) may fuel fires/explosions.

**Hazardous combustion products** Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

#### Explosion data

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### 5.3. Advice for firefighters

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Minimize dust generation and accumulation. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 5 / 13

Version 2.01

disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

## 7.2. Conditions for safe storage, including any incompatibilities

### Storage Conditions

Store as directed by product packaging.

## 7.3. Specific end use(s)

### Specific use(s)

Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

#### Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

#### Daptomycin

Pfizer OEL TWA-8 Hr: 300 µg/m<sup>3</sup>

#### Daptomycin

Germany TRGS

DS

RS

#### Citric acid

Czech Republic

4 mg/m<sup>3</sup>

Germany DFG

TWA-MAK: 2 mg/m<sup>3</sup>; I(2);inhalable fraction

Peak: 4 mg/m<sup>3</sup>; respirable fraction

Germany TRGS

TWA-AGW; 2 mg/m<sup>3</sup> (2(I)); inhalable fraction

Russia

MAC: 1 mg/m<sup>3</sup>

Switzerland

TWA-MAK: 2 mg/m<sup>3</sup>; inhalable dust

STEL-KZGW: 4 mg/m<sup>3</sup>; inhalable dust

#### Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m<sup>3</sup>

ACGIH TLV

Ceiling: 2 mg/m<sup>3</sup>

Austria

TWA-TMW: 2 mg/m<sup>3</sup>; inhalable fraction

STEL-KZGW: 4 mg/m<sup>3</sup> (8 X 5 min); inhalable fraction

Bulgaria

TWA: 2.0 mg/m<sup>3</sup>; alkaline aerosols

Czech Republic

1 mg/m<sup>3</sup>

Denmark

Ceiling: 2 mg/m<sup>3</sup>

Estonia

Ceiling: 2 mg/m<sup>3</sup>;

TWA: 1 mg/m<sup>3</sup>;

STEL: 2 mg/m<sup>3</sup>;

Finland

Ceiling: 2 mg/m<sup>3</sup>;

France

2 mg/m<sup>3</sup>

Hungary

TWA-AK: 1 mg/m<sup>3</sup>;

STEL-CK: 2 mg/m<sup>3</sup>;

Ireland

STEL: 2 mg/m<sup>3</sup>;

Ceiling Limit Value

2 mg/m<sup>3</sup>

Latvia

TWA: 0.5 mg/m<sup>3</sup>;

Poland

TWA-NDS: 0.5 mg/m<sup>3</sup>;

STEL-NDSch: 1 mg/m<sup>3</sup>;

Romania

TWA: 1 mg/m<sup>3</sup>;

STEL: 3 mg/m<sup>3</sup>;

Slovakia

TWA: 2 mg/m<sup>3</sup>;

Spain

STEL (VLA-EC): 2 mg/m<sup>3</sup>;

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 6 / 13

Version 2.01

Switzerland

TWA-MAK: 2 mg/m<sup>3</sup>; inhalable dust  
STEL-KZGW: 2 mg/m<sup>3</sup>; inhalable dust  
TWA: 2 mg/m<sup>3</sup>  
(vacated) Ceiling: 2 mg/m<sup>3</sup>  
STEL: 2 mg/m<sup>3</sup>;

OSHA PEL

United Kingdom

## 8.2. Exposure controls

### **Engineering controls**

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### **Personal protective equipment**

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### **Eye/face protection**

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### **Hand protection**

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### **Skin and body protection**

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### **Respiratory protection**

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### **Thermal hazards**

No information available.

### **Environmental exposure controls**

No information available.

## **Section 9: PHYSICAL AND CHEMICAL PROPERTIES**

### **9.1. Information on basic physical and chemical properties**

**Appearance**

Lyophilized powder

**Physical state**

Powder

**Color**

Light yellow to Light brown

**Odor**

No information available.

**Odor threshold**

No information available

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 7 / 13

Version 2.01

<u>Property</u>	<u>Values</u>
<b>Melting point / freezing point</b>	215
<b>Boiling point or initial boiling point and boiling range</b>	No data available
<b>Flammability (solid, gas)</b>	No data available
<b>Lower and upper explosion limit/flammability limit</b>	
<b>Lower explosion limit</b>	No data available
<b>Upper explosion limit</b>	No data available
<b>Flash point</b>	No data available
<b>Autoignition temperature</b>	No data available
<b>Decomposition temperature</b>	
<b>SADT (°C)</b>	No data available
<b>pH</b>	4.5-5.0
<b>pH (as aqueous solution)</b>	No data available
<b>Kinematic viscosity</b>	No data available
<b>Dynamic viscosity</b>	No data available
<b>Solubility</b>	No data available
<b>Water solubility</b>	Soluble in water
<b>Vapor pressure</b>	No data available
<b>Density and/or relative density</b>	No data available
<b>Bulk density</b>	No data available
<b>Liquid Density</b>	No data available
<b>Vapor density</b>	No data available
<b>Particle characteristics</b>	
<b>Particle Size</b>	No information available
<b>Particle Size Distribution</b>	No information available

## **Partition Coefficient: (Method, pH, Endpoint, Value)**

### Daptomycin

Predicted 7.4 Log D -9.719

## **9.2. Other information**

**Molecular formula**

Mixture

**Molecular weight**

Mixture

### **9.2.1. Information with regard to physical hazard classes**

No information available

### **9.2.2. Other safety characteristics**

No information available

## **Section 10: STABILITY AND REACTIVITY**

### **10.1. Reactivity**

**Reactivity** No information available.

### **10.2. Chemical stability**

**Stability** Stable under normal conditions.

#### **Explosion data**

**Sensitivity to mechanical impact** No information available.

**Sensitivity to static discharge** No information available.

### **10.3. Possibility of hazardous reactions**

**Possibility of hazardous reactions** No information available.

### **Hazardous polymerization**

Will not occur.

### **10.4. Conditions to avoid**

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions.

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 8 / 13

Version 2.01

## 10.5. Incompatible materials

### Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

## 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Short term

Accidental ingestion may cause effects similar to those seen in clinical use.

#### Known Clinical Effects:

Adverse effects associated with therapeutic use include headache, allergic skin rash, liver effects, effects on musculoskeletal system, muscle pain, muscle weakness, neuromuscular effects. Ingestion of this material may cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

#### Acute toxicity

Based on available data, the classification criteria are not met.

#### Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

#### Skin corrosion/irritation

Based on available data, the classification criteria are not met.

#### Respiratory or skin sensitization

Not tested, the classification criteria are not met.

#### STOT - single exposure

Not tested, the classification criteria are not met.

#### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure. Classification is based on mixture calculation methods based on component data.

#### Reproductive toxicity

Based on available data, the classification criteria are not met.

#### Germ cell mutagenicity

Based on available data, the classification criteria are not met.

#### Carcinogenicity

Not tested, the classification criteria are not met.

#### Aspiration hazard

Not tested, the classification criteria are not met.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Daptomycin

Rat Oral Minimum Lethal Dose > 2000 mg/kg

Rat Dermal Minimum Lethal Dose > 200 mg/kg

Mouse IV Minimum Lethal Dose > 700 mg/kg

Rat IV Minimum Lethal Dose > 140 mg/kg

#### Citric acid

Mouse Oral LD50 5400 mg/kg

#### Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Citric acid	= 3 g/kg ( Rat )	> 2000 mg/kg ( Rat )	-
Sodium hydroxide	= 325 mg/kg ( Rat )	= 1350 mg/kg ( Rabbit )	-

#### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Unknown acute toxicity

5 - 10 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist).

### Irritation / Sensitization: (Study Type, Species, Severity)

#### Daptomycin

Skin irritation Rabbit Slight

Eye irritation Rabbit Slight

#### Citric acid

Eye Irritation Rabbit Severe

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 9 / 13

Version 2.01

Skin Irritation Rabbit Mild

## Sodium hydroxide

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

## Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

### Daptomycin

1 Month(s) Rat Intravenous 10 mg/kg/day LOAEL Skeletal muscle, Kidney  
3 Month(s) Rat Intravenous 1 mg/kg/day LOAEL Skeletal muscle, Kidney  
6 Month(s) Rat Intravenous 2 mg/kg/day LOAEL Kidney, Skeletal muscle, Bone Marrow  
1 Month(s) Dog Intravenous 10 mg/kg/day LOAEL Bone Marrow, Skeletal muscle, Peripheral nervous system  
3 Month(s) Dog Intravenous 1 mg/kg/day NOAEL Skeletal muscle  
6 Month(s) Dog Intravenous 2 mg/kg/day NOAEL Skeletal muscle, Peripheral nervous system  
1 Month(s) Monkey Intravenous 10 mg/kg/day NOAEL None identified

## Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

### Daptomycin

Reproductive & Fertility Rat Intravenous 150 mg/kg/day NOAEL Negative: Fertility, Fetotoxicity  
Embryo / Fetal Development Rat Intravenous 75 mg/kg/day NOAEL Negative, Not Teratogenic  
Embryo / Fetal Development Rabbit Intravenous 75 mg/kg/day NOAEL Negative, Not Teratogenic  
Peri-/Postnatal Development Rat Intravenous 75 mg/kg/day NOAEL Negative: Fetotoxicity

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Daptomycin

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
Mammalian Cell Mutagenicity Not specified Negative  
Chromosome Aberration Chinese Hamster Ovary (CHO) cells Negative  
*In Vivo* Micronucleus Mouse Negative  
*In Vivo* Sister Chromatid Exchange Hamster Negative

**Carcinogenicity** None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Not tested, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Releases to the environment should be avoided. Environmental properties of the formulation have not been thoroughly investigated.

**Unknown aquatic toxicity** Contains 5 - 10 % of components with unknown hazards to the aquatic environment.

### 12.1. Toxicity

**No information available**

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 10 / 13

Version 2.01

## 12.3. Bioaccumulative potential

### Bioaccumulation

#### Partition Coefficient: (Method, pH, Endpoint, Value)

##### Daptomycin

Predicted 7.4 Log D -9.719

## 12.4. Mobility in soil

**Mobility in soil** No information available.

## 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
Citric acid	Not PBT/vPvB
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Not tested, the classification criteria are not met.

## 12.7. Other adverse effects

### **Other adverse effects**

No information available.

### **PMT or vPvM properties**

Not tested, the classification criteria are not met.

## **Section 13: DISPOSAL CONSIDERATIONS**

### 13.1. Waste treatment methods

#### **Waste from residues/unused products**

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## **Section 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation unless specified below.

**Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.**

**14.1 UN number:** Not applicable

**14.2 UN proper shipping name:** Not applicable

**14.3 Transport hazard class(es):** Not applicable

**14.4 Packing group:** Not applicable

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 11 / 13

Version 2.01

14.5 Environmental Hazard(s): Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Daptomycin

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>EINECS</b>	Not Listed
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 4

Citric acid

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	201-069-1
<b>AICS</b>	Present

Sodium hydroxide

<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	1000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	215-185-5
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

### National regulations

#### Germany

**Chemical Prohibition Ordinance (ChemVerbotsV)**

Not applicable

TRGS 905

Not applicable

#### Switzerland

**Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018** Not applicable

**Storage of Hazardous Material** Not applicable

**WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20** Not applicable

**Major Accidents Ordinance SR 814.012** Not applicable

#### European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

#### **Authorizations and/or restrictions on use:**

This product contains one or more substance(s) subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH	Substance subject to authorization per
---------------	--------------------------------	----------------------------------------

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 12 / 13

Version 2.01

	Annex XVII	REACH Annex XIV
Citric acid 77-92-9	75	-
Sodium hydroxide 1310-73-2	75	-

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## Biocidal Products Regulation (EU) No 528/2012 (BPR)

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
Citric acid 77-92-9	Product-type 2: Disinfectants and algicides not intended for direct application to humans or animals Product-type 6: Preservatives for products during storage

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H314 - Causes severe skin burns and eye damage. H373 - May cause damage to organs through prolonged or repeated exposure.

H319 - Causes serious eye irritation.

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reason for revision** Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

# SAFETY DATA SHEET

Product Name Daptomycin for Injection (rapid reconstitution) (Hospira, Inc.)  
Revision date 10-Jun-2026

Page 13 / 13

Version 2.01

---

Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

**Revision date** 10-Jun-2026

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**